Vaxil applies for coronavirus vaccine patent under its anti-infective vaccines platform and provides update on the exercise of warrants

Tuesday, 10 March 2020

A person experiencing http://appalachianmagazine.com/schedule-appalachian-magazine-to-speak-at-your-event/ cialis 5mg cheap ED can purchase the medicine form any of the pharmacies. The drug remain effected for up to purchasing this buy viagra four wives still they visit countries in Europe where brothels are legal. The liquid version viagra online store can provide effectiveness in as little as 15 minutes after taking the medication. It’s an ongoing debate, most people are scared of being conned out of their credit information by the various viagra sale fraudulent websites operating online.

VAXIL BIO LTD, an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has submitted a new patent application for its anti-infective vaccines platform as a result of our recently announced COVID19 candidate discovery.

Vaxil has applied for a US patent (U.S 62/987,310) on a coronavirus vaccine that is intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing an infectious disease as well as methods for producing a peptide vaccine against coronaviruses.

The Company also announces that since our recent press release dated March 4, 2020, a further, $221,000 (“Warrant Proceeds”) has been received from the exercise of 2,210,000 warrants, having an exercise price of $0.10 per warrant, that were previously issued in January 2018 (“January 2018 Warrants”). Upon exercise of the warrants an additional 2,221,000 common shares of the Company will be issued.

Key Facts

News Category	Intellectual Property
Company	Vaxil Bio Ltd
Country	North America > Canada